Neutrophils Efficiently Cross-prime Naive T Cells in Vivo
Overview
Authors
Affiliations
Neutrophils are professional phagocytes that migrate early, in high number, to the infection sites. Our study has analyzed how neutrophils cross-present antigens and influence CD8+ T-cell responses. By using highly purified neutrophils from peritoneal exudates and bone marrow, we have shown that neutrophils cross-present ovalbumin to a CD8+ T-cell hybridoma and to naive CD8+ T cells from OT1 transgenic mice. Cross-presentation by neutrophils was TAP and proteasome dependent and was as efficient as in macrophages. Moreover, it actually occurred earlier than in professional antigen-presenting cells. Peritoneal exudate neutrophils from mice injected intraperitoneally with ovalbumin also cross-presented ovalbumin, proving that neutrophils take up and present exogenous antigens into major histocompatibility complex I (MHC I) molecules in vivo. We then evaluated the in vivo influence of antigen cross-presentation by neutrophils on CD8+ T-cell response using beta2-microglobulin-deficient mice transferred with OT1 CD8+ T cells and injected with ovalbumin-pulsed neutrophils. Four days after neutrophil injection, OT1 cells proliferated and expressed effector functions (IFN-gamma production and cytolysis). They also responded efficiently to a rechallenge with ovalbumin-pulsed dendritic cells in CFA. These data are the first demonstration that neutrophils cross-prime CD8+ T cells in vivo and suggest that they may constitute, together with professional antigen-presenting cells, an attractive target to induce cytotoxic T cells in vaccines.
Neutrophil Engulfment in Cancer: Friend or Foe?.
Lu T, Li W Cancers (Basel). 2025; 17(3).
PMID: 39941753 PMC: 11816126. DOI: 10.3390/cancers17030384.
Targeting Cancer: Microenvironment and Immunotherapy Innovations.
Padzinska-Pruszynska I, Taciak B, Kiraga L, Smolarska A, Gorczak M, Kucharzewska P Int J Mol Sci. 2025; 25(24.
PMID: 39769334 PMC: 11679359. DOI: 10.3390/ijms252413569.
Stinson J, Sheen A, Lax B, Yang G, Duhamel L, Santollani L Mol Cancer Ther. 2024; 24(1):118-130.
PMID: 39382078 PMC: 11695183. DOI: 10.1158/1535-7163.MCT-24-0163.
Li X, Hu L, Naeem A, Xiao S, Yang M, Shang H Int J Nanomedicine. 2024; 19:2851-2877.
PMID: 38529365 PMC: 10961241. DOI: 10.2147/IJN.S449181.
Feola S, Hamdan F, Russo S, Chiaro J, Fusciello M, Feodoroff M J Immunother Cancer. 2024; 12(3).
PMID: 38458776 PMC: 10928783. DOI: 10.1136/jitc-2023-008342.